ACTG 265--SAFETY AND IMMUNOGENICITY OF LIVE ATTENUATED VARICELLA VACCINE

ACTG 265--水痘减毒活疫苗的安全性和免疫原性

• 批准号: 6281428
• 负责人: SANDRA BURCHETT
• 金额: $ 2.01万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6281428
• 关键词: HIV infections; attenuated microorganism; chickenpox; child (0-11); clinical research; clinical trial phase I; data collection; drug screening /evaluation; human subject; human therapy evaluation; immunity; immunotherapy; live vaccine; pediatric AIDS; viral vaccines

This study is a phase I/II pediatric ACTG trial of the safety and immunogenicity of live attenuated varicella vaccine in HIV-infected children with minimal immunodeficiency. The purpose is to examine the effects of a live-attenuated varicella vaccine on HIV-infected children. The primary questions to be answered concern the safety of the vaccine, when used within this patient population, and the extent to which these subjects are capable of mounting an immune response to the vaccine. Data from a comparison group of HIV-infected subjects with a history of wild type varicella, will be collected. The data will be used to examine whether the vaccine is capable of evoking immune responses similar to those mounted against the disease itself.

本研究是一项I/II期儿童ACTG试验， 水痘减毒活疫苗免疫原性研究 免疫力低下的儿童。目的是检查 减毒水痘活疫苗对艾滋病毒感染儿童的影响。 需要回答的主要问题涉及疫苗的安全性， 当在该患者人群中使用时， 受试者能够对疫苗产生免疫应答。数据 从一组有野生动物史的HIV感染者中， 型水痘，将被收集。这些数据将用于检查 疫苗是否能够引起类似于 这些都是针对疾病本身的。